[{"bbox": [91, 99, 367, 130], "category": "Page-header", "text": "Q-Line Biotech Limited"}, {"bbox": [231, 169, 1516, 262], "category": "Section-header", "text": "ANNEXURE – F\nRESTATED CONSOLIDATED STATEMENT OF OTHER CURRENT LIABILITIES AND SHORT TERM PROVISIONS"}, {"bbox": [1277, 266, 1557, 295], "category": "Text", "text": "(Amount in Rs. Lakhs)"}, {"bbox": [91, 295, 1557, 1282], "category": "Table", "text": "<table><thead><tr><th rowspan=\"2\">Particulars</th><th colspan=\"3\">As at</th></tr><tr><th>31-03-2025</th><th>31-03-2024</th><th>31-03-2023</th></tr></thead><tbody><tr><td><strong>Other Current Liabilities</strong></td><td></td><td></td><td></td></tr><tr><td>Interest Accrued but not due</td><td>70.69</td><td>24.94</td><td>12.57</td></tr><tr><td>Advances received against sale of Land</td><td>300.00</td><td>-</td><td>-</td></tr><tr><td>Current Maturities of finance lease obligations</td><td>134.48</td><td>-</td><td>-</td></tr><tr><td>Statutory Payables</td><td>386.71</td><td>90.75</td><td>92.79</td></tr><tr><td>Advances Received from Customers *</td><td>66.12</td><td>635.99</td><td>48.46</td></tr><tr><td>Provision for expenses</td><td>1,245.68</td><td>655.75</td><td>269.44</td></tr><tr><td>Income Received in Advance</td><td>69.75</td><td>67.16</td><td>50.31</td></tr><tr><td>Director Remuneration Payable</td><td>13.63</td><td>12.49</td><td>21.99</td></tr><tr><td>Salary Payable to Staff</td><td>211.30</td><td>177.20</td><td>117.13</td></tr><tr><td><strong>Total</strong></td><td><strong>2,498.35</strong></td><td><strong>1,664.27</strong></td><td><strong>612.69</strong></td></tr><tr><td><strong>Short Term Provisions</strong></td><td></td><td></td><td></td></tr><tr><td>Provision for Gratuity Expenses</td><td>31.08</td><td>22.47</td><td>18.83</td></tr><tr><td>Provision for Income Tax Net of Advances, TDS, TCS</td><td></td><td></td><td></td></tr><tr><td>(A) Provision of Income Tax</td><td>1,886.03</td><td>839.72</td><td>861.51</td></tr><tr><td>(B) Advance Tax</td><td>400.00</td><td>550.00</td><td>500.00</td></tr><tr><td>(C) TDS/TCS collected</td><td>73.80</td><td>54.18</td><td>82.87</td></tr><tr><td><strong>Provision for Income Tax Net of Advances, TDS, TCS (A-B-C)</strong></td><td><strong>1,412.23</strong></td><td><strong>235.54</strong></td><td><strong>278.64</strong></td></tr><tr><td>(B) Interest u/s 234 B/C of Income Tax</td><td>156.36</td><td>-</td><td>-</td></tr><tr><td><strong>Total Short Term provision</strong></td><td><strong>1,599.67</strong></td><td><strong>258.01</strong></td><td><strong>297.48</strong></td></tr><tr><td>*Includes advances received from Related parties</td><td>45.01</td><td>530.63</td><td>-</td></tr></tbody></table>"}, {"bbox": [91, 1316, 166, 1343], "category": "Section-header", "text": "Notes:"}, {"bbox": [91, 1347, 1557, 1412], "category": "Text", "text": "1. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, V, I, II and III."}, {"bbox": [1349, 1442, 1557, 1471], "category": "Section-header", "text": "ANNEXURE – G"}, {"bbox": [298, 1507, 1349, 1540], "category": "Text", "text": "Restated Consolidated Statement Of Property, Plant & Equipment and Intangible Assets"}, {"bbox": [91, 1540, 229, 1567], "category": "Text", "text": "FY 2022-23"}, {"bbox": [802, 2170, 849, 2199], "category": "Page-footer", "text": "214"}]